Effects of statin therapy on the progression of chronic kidney disease

Advances in Chronic Kidney Disease

Volumn 12, Issue 2, 2005, Pages 187-195

  Shah, Samir ^a   Paparello, James ^a   Danesh, Farhad R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Cholesterol; Chronic renal disease; Dyslipidemia; Statin

Indexed keywords

AMINOTRANSFERASE; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; COMPACTIN; CREATINE KINASE; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BILE LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; HEMATURIA; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER INJURY; MORTALITY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RASH; RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; TREATMENT OUTCOME;

EID: 16844368589     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2005.01.007     Document Type: Article

References (62)

1. B.L. Kasiske Hyperlipidemia in patients with chronic renal disease Am J Kidney Dis 32 suppl 1998 S142 S156
2. B.F. Palmer, R.J. Alpern Treating dyslipidemia to slow the progression of chronic renal failure Am J Med 114 2003 411 412
3. R. Walter, H. Mischak, H. Haller Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESRD patients Nephrol Dial Transplant 17 2000 24 29
4. C. Baigent, D.C. Wheeler Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? Nephrol Dial Transplant 15 2000 1118 1119
5. W. Tschope, M. Koch, E. Ritz Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis Nephron 64 1993 354 358
6. J. Chen, P. Munter, L.L. Hamm The metabolic syndrome and chronic kidney disease in U.S. adults Ann Intern Med 140 2004 167 174
7. S. Vazquez-Perez, P. Aragoncillo, N. de las Heras Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits Nephrol Dial Transplant 16 2001 40 44
8. L.F. Fried, T.J. Orchard, B.L. Kasiske Effect of lipid reduction on the progression of renal disease A meta-analysis Kidney Int 59 2001 260 269
9. H. Oda, W.F. Keane Recent advances in satins and the kidney Kidney Int 71 suppl 1999 S2 S5
10. M.D. Bentley, M. Rodriguez-Porcel, A. Lerman Enhanced renal cortical vascularization in experimental hypercholesterolemia Kidney Int 61 2002 1056 1063
11. A.R. Chade, M. Rodriguez-Porcel, J. Grande Distinct renal injury in early atherosclerosis and renovascular disease Circulation 106 2002 1165 1171
12. S.H. Wilson, A.R. Chade, L.O. Lerman Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia Nephrol Dial Transplant 18 2003 703 709
13. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals A randomised placebo-controlled trial Lancet 360 2002 7 22
14. V.G. Athyros, A.A. Papageorgiou, B.R. Mercouris Treatment with atorvastatin to the national cholesterol educational program goals versus usual care in secondary coronary heart disease prevention. The Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study Curr Med Res Opin 18 2002 220 228
15. T.R. Pedersen, J. Kjekshus, K. Berg Cholesterol lowering and the use of healthcare resources Results of the Scandinavian simvastatin survival study Circulation 93 1996 1796 1802
16. A.M. Gotto Jr, E. Whitney, E.A. Stein relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 2000 477 484
17. M. Tonelli, L. Moye, F.M. Sacks Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease J Am Soc Nephrol 14 2003 1605 1613
18. P.-O. Attman, O. Samuelsson, P. Alaupovic Lipoprotein metabolism and renal failure Am J Kidney Dis 6 1993 573 579
19. O. Samuelsson, H. Mulec, C. Knight-Gibson Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency Nephrol Dial Transplant 12 1997 1908 1915
20. M. Sahadevan, B.L. Kasiske Hyperlipidemia in kidney disease Causes and consequences Curr Opin Nephrol Hypertens 11 2002 323 329
21. M.J. Landray, J. Thambyrajah, F.J. McGlynn Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment Am J Kidney Dis 38 2001 537 546
22. A.S. Go, G.M. Chertow, D. Fan Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation 106 2002 3143
24. F. Locatelli, P. Pozzoni, L. Del Vecchio Epidemiology of cardiovascular risk in patients with chronic kidney disease Nephrol Dial Transplant 18 2003 2 9
25. E.G. Lowrie, N.L. Lew Death risk in hemodialysis patients The predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 1990 458 482
26. C. Baigent, K. Burbury, D.C. Wheeler Premature cardiovascular disease in chronic renal failure Lancet 356 2000 147 151
27. D.C. Miskulin, K.B. Meyer, A.S. Levey Comorbidity and other factors associated with modality selection in incident dialysis patients the CHOICE study Am J Kidney Dis 39 2002 324 336
28. E.G. Lowrie, N.L. Lew Commonly measured laboratory variables in hemodialysis patients Relationships among them and to death risk Semin Nephrol 12 1992 276 283
29. W.F. Keane Lipids and the kidney Kidney Int 46 1994 910 920
30. J.F. Moorhead, M.K. Chan, M. El Nahas Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial diesase Lancet 11 1982 1309 1311
31. B.L. Kasiske, M.P. Cleary, M.P. O'Donnell Effects of genetic obesity on renal structure and function in the Zucker rat J Lab Clin Med 106 1985 598 604
32. B.L. Kasiske, M.P. O'Donnell, W.F. Keane Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats Kidney Int 33 1988 667 672
33. B.L. Kasiske, M.P. O'Donnell, M.P. Cleary Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats Kidney Int 35 1989 40 47
34. B.L. Kasiske, M.P. O'Donnell, P.G. Schmitz Renal injury of diet-induced hypercholesterolemia in rats Kidney Int 37 1990 880 891
35. W.F. Keane, B.L. Kasiske, M.P. O'Donnell Lipids and progressive glomerulosclerosis A model analogous to atherosclerosis Am J Nephrol 8 1988 261 271
36. L.G. Hunsicker, S. Adler, A. Caggiula Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study Kidney Int 51 1997 1908 1919
37. S.L. Seliger, N.S. Weiss, D.L. Gillen HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients Kidney Int 61 2002 297 304
38. M. Manttari, E. Tiula, T. Alikoski Effects of hypertension and dyslipidemia on the decline in renal function Hypertension 26 1995 670 675
39. E.S. Schaeffner, T. Kurth, G.C. Curhan Cholesterol and the risk of renal dysfunction in apparently healthy men J Am Soc Nephrol 14 2003 2084 2091
40. C.M. White A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin J Clin Pharmacol 42 2002 963 970
41. R.H. Stern, B.B. Yang, M. Horton Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin J Clin Pharmacol 37 1997 816 819
42. R.H. Stern, B.B. Yang, N.J. Hounslow Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor J Clin Pharmacol 40 2000 616 623
43. S.M. Singhvi, H.Y. Pan, R.A. Morrison Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects Br J Clin Pharmacol 29 1990 239 243
44. T. Hatanaka Clinical pharmacokinetics of pravastatin Mechanisms of pharmacokinetic events Clin Pharmacokinet 39 2000 397 412
45. R. Agarwal Statin induced proteinuria Renal injury or renoprotection? J Am Soc Nephrol 15 2004 2502 2503
46. A. Verhulst, P.C. D'Haese, M.E. De Broe Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells J Am Soc Nephrol 15 2004 2249 2257
47. J.E. Sidaway, R.G. Davidson, F. McTaggart Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells J Am Soc Nephrol 15 2004 2258 2265
48. J. Buse Statin treatment in diabetes mellitus Clin Diabetes 21 2003 168 172
49. P.D. Thompson, P. Clakson, R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690
50. V.G. Athyros, A.A. Papageorgiou, M. Elisaf Statins and renal function in patients with diabetes mellitus Curr Med Res Opin 19 2003 615 617
51. H. Holdaas, B. Fellstrom, T.R. Pedersen Effect of fluvastatin on cardiac outcomes in renal transplant recipients A multicentre, randomised, placebo-controlled trial Lancet 361 2003 2024 2031
52. S. Bianchi, R. Bigazzi, A. Caiazza A Controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 2003 565 570
53. C. Baigent, M. Landry Study of heart and renal protection (SHARP) Kidney Int 84 suppl 2003 S207 S210
54. C. Wanner, V. Krane, E. Ritz Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study) demographic and baseline characteristics Kidney Blood Press Res 27 2004 259 266
55. F.R. Danesh, M.M. Sadeghi, Y.S. Kanwar 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway Implications for diabetic nephropathy Proc Natl Acad Sci USA 99 2002 8301 8305
56. L. Zeng, H. Xu, F.R. Danesh Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated up-regulation of p27 J Am Soc Nephrol 15 2004 1711 1720
57. L.M. Blanco-Colio, A. Villa, M. Ortego 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation Atherosclerosis 161 2002 17 26
58. T. Maeda, A. Matsunuma, N. Horiuchi Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells Biochem Biophys Res Commun 280 2001 874 877
59. R.R. Mattingly, R.A. Gibbs, J.J. Reiners Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase J Pharmacol Exp Ther 303 2002 74 81
60. J.K. Park, D.N. Muller, H. Haller Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects Kidney Int 58 2000 1420 1430
61. M.P. O'Donnell, B.L. Kasiske, W.F. Keane Lovastatin retards the progression of established glomerular disease in obese Zucker rats Am J Kidney Dis 22 1993 83 89
62. A. Yoshimura, K. Inui, T. Ideura Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis J Am Soc Nephrol 9 1998 2027 2039